CD274 and neoplasm: These neutrophils deliver BMS‐202 to block PD‐1/PD‐L1 and carfilzomib to polarize macrophages into M1‐type, transforming the tumor microenvironment into an immunogenic state and achieving effective therapy in MM‐bearing mouse models.